Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone781-577-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/7/2019 (Confirmed)
OptionableNot Optionable
Senesco Technologies (NYSE:ELOX) Frequently Asked Questions
What is Senesco Technologies' stock symbol?
Senesco Technologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "ELOX."
How were Senesco Technologies' earnings last quarter?
Senesco Technologies Inc. (NYSE:ELOX) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.33) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.08. View Senesco Technologies' Earnings History.
When is Senesco Technologies' next earnings date?
What is the consensus analysts' recommendation for Senesco Technologies?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Senesco Technologies in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Senesco Technologies.
Has Senesco Technologies been receiving favorable news coverage?
News articles about ELOX stock have trended extremely negative this week, InfoTrie Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Senesco Technologies earned a media sentiment score of -4.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Senesco Technologies.
Who are some of Senesco Technologies' key competitors?
Some companies that are related to Senesco Technologies include Concordia International (CXR), Polynovo (PNV), Mesoblast (MSB), Neptune Wellness Solutions (NEPT), Oxford BioMedica (OXB), Kodiak Sciences (KOD), Starpharma (SPL), Resverlogix (RVX), BELLUS Health (BLU), Biotest (BIO), ProMetic Life Sciences (PLI), Theratechnologies (TH), Monash IVF Group (MVF), Emerald Health Therapeutics (EMH) and Paradigm Biopharmaceuticals (PAR).
What other stocks do shareholders of Senesco Technologies own?
Who are Senesco Technologies' key executives?
Senesco Technologies' management team includes the folowing people:
- Mr. Robert E. Ward, Chairman & CEO (Age 61)
- Dr. Silvia Noiman, Founder & Director (Age 62)
- Mr. Gregory L. Weaver CPA, M.B.A., Chief Financial Officer (Age 62)
- Dr. Gregory Williams, COO & Interim Chief Medical Officer (Age 59)
- Ms. Barbara Ryan, Investor Relations Officer
How do I buy shares of Senesco Technologies?
Shares of ELOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Senesco Technologies' stock price today?
One share of ELOX stock can currently be purchased for approximately $8.24.
How big of a company is Senesco Technologies?
What is Senesco Technologies' official website?
How can I contact Senesco Technologies?
The company can be reached via phone at 781-577-5300.
MarketBeat Community Rating for Senesco Technologies (NYSE ELOX)
MarketBeat's community ratings are surveys of what our community members think about Senesco Technologies and other stocks. Vote "Outperform" if you believe ELOX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELOX will underperform the S&P 500 over the long term. You may vote once every thirty days.
